Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Quanta Services Inc (PWR) Price & Performance

AbCellera Biologics IncTrade
Quanta Services IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Quanta Services Inc — how do they compare? AbCellera Biologics Inc trades at $9.99 (market cap $2.99B), while Quanta Services Inc trades at $687.02 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 33.7× AbCellera Biologics Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLPWR
Market Cap
$2.99B$100.82B
Sector
HealthIndustrials
52-Week High
$9.76$785.24
52-Week Low
$2.78$372.50
Enterprise Value
$2.58B$106.91B
Dividend Yield
0.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Quanta Services Inc

PWR trades at $680.97, up 3.04% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth, reaching $28.48B in 2025, and raised its 2026 outlook, supported by a record backlog and infrastructure demand. However, valuation ratios like a P/E of 76.73 and P/S of 3.1 are elevated, indicating high expectations.

The outlook is positive due to accelerating infrastructure investments and analyst consensus favoring buys, with a price target of $809.75. Risks include high valuation sensitivity, project execution challenges, and macroeconomic pressures on capital spending. Earnings growth remains the key catalyst for further upside, but investors should weigh premium pricing against execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Quanta Services Inc

Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.

Read more on PWR